美康生物(300439) - 2018 Q3 - 季度财报

Financial Performance - Operating revenue for the reporting period was ¥890,511,419.71, representing a year-on-year growth of 33.53%[8] - Net profit attributable to shareholders was ¥70,546,172.94, reflecting a 6.47% increase compared to the same period last year[8] - The net profit after deducting non-recurring gains and losses was ¥65,743,544.21, up by 13.13% year-on-year[8] - The basic earnings per share for the reporting period was ¥0.2033, a 6.44% increase compared to the previous year[8] - Total operating revenue for the first nine months increased by 33.34% compared to the same period last year, driven by expanded sales scale[17] - Total operating revenue for Q3 2018 reached CNY 890.51 million, a 33.5% increase from CNY 666.91 million in the same period last year[35] - Net profit for Q3 2018 was CNY 75.98 million, representing a 5.3% increase compared to CNY 72.51 million in Q3 2017[37] - The company's operating revenue for the current period was approximately ¥919.33 million, an increase of 23.2% compared to ¥746.09 million in the previous period[48] - Net profit for the current period was approximately ¥161.67 million, a decrease of 10.1% compared to ¥179.94 million in the previous period[49] Assets and Liabilities - Total assets at the end of the reporting period reached ¥4,442,084,529.29, an increase of 3.82% compared to the previous year[8] - The company's total assets increased to CNY 3.60 billion, up from CNY 3.24 billion at the beginning of the period, reflecting a growth of 11.1%[33] - Current liabilities totaled CNY 1.93 billion, an increase of 8.3% from CNY 1.78 billion at the start of the period[32] - Long-term borrowings rose to CNY 132.68 million, significantly higher than CNY 18.15 million in the previous period[32] - The company's long-term borrowings increased by 631.02% at the end of the reporting period compared to the beginning of the year, attributed to business expansion and new long-term loans[17] Cash Flow - The net cash flow from operating activities for the year-to-date was ¥13,314,818.99, showing a significant increase of 134.84%[8] - Cash flow from operating activities increased by 134.84% year-on-year for the first nine months, reflecting improved sales and increased collection of receivables[18] - Cash flow from operating activities increased to approximately ¥2.37 billion, up 26.6% from ¥1.87 billion in the previous period[51] - The net cash flow from financing activities was ¥365,125,439.49, an increase from ¥293,447,759.59 year-over-year[56] - The cash flow from investment activities showed a significant outflow, indicating potential investments or acquisitions[56] Shareholder Information - The total number of shareholders at the end of the reporting period was 20,998[11] - The largest shareholder, Zou Bingde, holds 50.76% of the shares, amounting to 176,124,291 shares[11] - The company repurchased and canceled 563,600 restricted stocks at prices of 13.185 yuan and 13.575 yuan per share, accounting for 0.1624% of the total share capital[19] Expenses - Total operating costs amounted to CNY 814.89 million, up 40.0% from CNY 582.24 million year-over-year[35] - The company reported a significant increase in R&D expenses, which reached CNY 23.19 million, compared to CNY 22.39 million in the previous year[35] - Research and development expenses decreased to CNY 8,636,941.20 from CNY 12,150,185.73, a reduction of about 28.76%[40] - Sales expenses increased to approximately ¥127.37 million, up 41.5% from ¥90.02 million in the previous period[48] Other Financial Metrics - The weighted average return on net assets was 3.41%, an increase of 0.20% from the previous year[8] - The company reported non-recurring gains totaling ¥29,688,796.07 for the year-to-date[9] - The company reported a total comprehensive income of CNY 102,279,207.72, compared to CNY 80,378,885.12 in the previous period, marking an increase of approximately 27.24%[41] - The company experienced an asset impairment loss of CNY 22,169,818.85, compared to a gain of CNY 1,521,823.31 in the previous period[41] Cash and Cash Equivalents - The balance of cash and cash equivalents at the end of the reporting period was approximately 393.64 million yuan, up from 378.84 million yuan at the beginning of the year[28] - The company reported a cash and cash equivalents balance of approximately ¥393.76 million at the end of the period, up from ¥248.57 million in the previous period[53] - The cash and cash equivalents at the end of the period were ¥212,015,732.41, down from ¥121,914,451.50 in the previous year[56] - The company's cash and cash equivalents decreased by ¥52,075,353.92 during the quarter[56] Audit and Reporting - The company did not undergo an audit for the third quarter report[57] - The chairman of the company is Zou Bingde, who presented the report on October 26, 2018[58]